3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Burkitt Lymphoma
22
Lymphoma, Large B-Cell, Diffuse
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Lymphoma, Follicular
12
Lymphoma
11
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Rhabdomyosarcoma
8
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, B-Cell
6
Leukemia, Biphenotypic, Acute
6
Wilms Tumor
5
Sarcoma, Ewing
5
Recurrence
5
Neuroblastoma
5
Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma, T-Cell
4
Rhabdomyosarcoma, Embryonal
3
Medulloblastoma
3
Lymphoproliferative Disorders
3
Lymphoma, Mantle-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Down Syndrome
3
Sarcoma
2
Rhabdomyosarcoma, Alveolar
2
Rhabdoid Tumor
2
Plasmablastic Lymphoma
2
Osteosarcoma
2
Interventions
Cyclophosphamide
5
ibrutinib
4
fludarabine
4
pirtobrutinib
3
obinutuzumab
3
acalabrutinib
3
fludarabine phosphate
2
Rituximab
2
Mesna
2
venetoclax
1
ricolinostat
1
idelalisib
1
Whole-Body Irradiation
1
Vincristine
1
Tacrolimus
1
Stem Cell Transplantation
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Melphalan
1
Leukapheresis
1
Doxorubicin
1
Diet
1
Busulfan
1
Bone Marrow Transplantation
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
Vincristine
×
90 days
×
Clear all
NCT06564038
2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2
Recruiting
408 enrolled